Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet,
an Expert Panel was selected according to the framework elements of the National Institutes …

Improvements in early detection, supportive care, and treatment have resulted in an
increasing number of cancer survivors, with a current 5-year relative survival rate for all …

Summary Background The MInT study was the first to show improved 3-year outcomes with
the addition of rituximab to a CHOP (cyclophosphamide, doxorubicin, vincristine, and …

B cells foster squamous cell carcinoma (SCC) development through deposition of
immunoglobulin-containing immune complexes in premalignant tissue and Fcγ receptor …

Background Long-term outcomes after multiple courses of rituximab among children with
frequently relapsing, steroid-dependent nephrotic syndrome (FRSDNS) are unknown …

Therapy-related acute myeloid leukemia (tAML) is a rare but highly fatal complication of
cytotoxic chemotherapy. Despite major changes in cancer treatment, data describing tAML …

Immune system detects foreign pathogens, distinguishes them from self-antigens and
responds to defend human body. When this self-tolerance is disrupted, the overactive …

Patients with chronic lymphocytic leukemia (CLL) are known to have an increased incidence
of second cancers, but the contribution of commonly used frontline therapies to the …

B cells are major effector cells in autoimmunity through antibody production, T cell help and
pro-inflammatory cytokine production. Major advances have been made in human B cell …

Tumour-infiltrating immune cells have been widely implicated to play a significant role in
carcinogenesis, through both pro-or anti-tumour effects. The multi-faceted effects of lung …